{
  "docId": "019de075-5375-74ac-b63e-223f7dcbcdee",
  "docSlug": "1e5a737805b52115da5825472ef93325",
  "documentTitle": "Hillstream BioPharma | Investor Presentation Deck | 19 slides",
  "authorId": "hillstream-biopharma",
  "authorName": "Hillstream BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 19,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "Scientific illustration of a bispecific antibody binding to a HER2-HER3 dimer.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-5375-74ac-b63e-223f7dcbcdee/11",
  "deckHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee",
  "deckJsonHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee.json",
  "deckAnchorHref": "/decks/019de075-5375-74ac-b63e-223f7dcbcdee#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.25,
        "x": 0.25,
        "y": 0.15
      },
      "kind": "image",
      "text": "Diagram of bispecific antibody binding to HER2-HER3 dimer",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3263719-0f9f-4acf-9355-4b6fa8a24e50",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.5,
        "y": 0.2
      },
      "kind": "list",
      "text": "HER3 has weak oncogenic activity alone\nDimerizing with HER2 causes profound oncogenesis with increased metastatic potential\nNovel epitope binding can prevent HER3 dimerization\nBinding to conformational epitopes on HER2 can aid in reducing signal transduction intracellularly\nCapable of creating multiple bispecific compounds for future development\nBispecific antibodies can be developed into pipeline ADC compounds",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "679003e5-3f6e-431c-b1da-d14cf8b2581c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.28,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1. Uliano J, et. al. ESMO 2023 Feb;8(1):100790. doi: 10.1016/j.esmoop.2023.100790\n2. Diwanji D, et. al. Nature. 2021 Dec;600(7888):339-343. doi: 10.1038/s41586-021-04084-z",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52e67359-2f23-41e5-8819-9772609c07f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Bispecific Antibodies Targeting HER2 & HER3",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "823731db-e700-4bde-8d74-de555e0f3061",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 4,
      "beatId": "e53add27-632d-4b4f-baf0-308f53797da9",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 4-14 present the company's solution, including the lead program HSB-3215 and its technical advantages",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}